Blood test for diagnosing lung cancer
Establishing a Diagnosis of Lung Cancer Through a Fluid Biopsy
University of Southern California · NCT04162678
This study is testing a blood test to see if it can accurately diagnose lung cancer in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Southern California (other) |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Los Angeles, California and 1 other locations) |
| Trial ID | NCT04162678 on ClinicalTrials.gov |
What this trial studies
This observational trial collects blood samples through fluid biopsy to diagnose lung cancer. The primary goal is to estimate the sensitivity and specificity of this method for identifying bronchogenic carcinoma. Secondary objectives include determining the accuracy of histologic subtype identification and evaluating the contributions of various assays in diagnosis. Patients will have their blood samples analyzed and will be followed for up to one year to assess outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals scheduled for a diagnostic biopsy for suspected lung cancer or those who have recently undergone such a biopsy.
Not a fit: Patients who have received chemotherapy or radiotherapy within the last four weeks or have other active solid tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to a non-invasive blood test for early detection of lung cancer.
How similar studies have performed: Other studies have shown promise in using liquid biopsies for cancer diagnosis, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled to undergo a diagnostic biopsy for possible lung cancer or * Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet undergone treatment or * Planning or completed in the last 2 weeks a CT lung cancer screen * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study * Known other solid tumor malignancy other than lung cancer requiring ongoing active treatment
Where this trial is running
Los Angeles, California and 1 other locations
- Los Angeles County-USC Medical Center — Los Angeles, California, United States (RECRUITING)
- USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Jorge J Nieva, MD — University of Southern California
- Study coordinator: Sandy Tran, RN
- Email: Sandy.Tran@med.usc.edu
- Phone: 323-865-0451
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Carcinoma